SUMMARY The effects of encainide on ventricular arrhythmia and left ventricular function were studied in 21 patients with chronic, high-grade ventricular arrhythmia using a prospective, 3-month, placebo-controlled, single-blind trial design.
ENCAINIDE, a benzanillide derivative, is a new antiarrhythmic agent recently shown to have great efficacy in suppressing ventricular ectopy.`Initial electrophysiologic studies in animals have shown that encainide decreases automaticity, reduces the upstroke velocity and duration of the cardiac action potential and concurrently prolongs the effective refractory period of the action potential.' Subsequent studies have shown that encainide is effective in suppressing atrial and ventricular arrhythmias in a variety of species with varying experimental interventions.2 '3 This study was designed to prospectively investigate the effectiveness of encainide given orally every 6 hours in reducing the frequency of ventricular premature complexes (VPCs) as confirmed on frequent ambulatory electrocardiographic recordings, serial exercise tests and invasive electrophysiologic tests.
To minimize the effects of spontaneous variability on VPC frequency,8-10 patients with chronic, high-frequency ventricular arrhythmia were studied. In addition, the study design included quantification of ventricular arrhythmia during multiple 24-hour ambulatory ECG recordings obtained during alternating placebo and encainide treatment phases. The effects of encainide on exercise-related ventricular arrhythmia were also evaluated during treadmill testing. Exercise duration and myocardial performance were studied off and on encainide using treadmill exercise testing and radionuclide cineangiography at rest and during exercise. The electrophysiologic effects of acute i.v. and chronic oral encainide, including the response to provocative extrastimulus techniques, were determined at cardiac catheterization.", 12 
Methods
Patient Characteristics (table 1) All patients were older than 21 years of age and had a history of frequent ventricular arrhythmias (minimum mean VPC frequency . 60 beats/hour for at least 48 hours) for more than 3 months, without known reversible cause. No other antiarrhythmic agents were allowed during the trial; however, digitalis, diuretics and potassium supplements for patients with congestive heart failure and A-blocking agents for patients with angina pectoris were continued without modification (table 1). Each patient gave informed consent before the study. The protocol was approved by the human research committees of the participating institutions. Additional informed Abbreviations: CABG = coronary artery bypass grafting; CAD = coronary artery disease; CHF = congestive heart failure; D = disopyramide; DPH = diphenylhydantoin; HBP = high blood pressure; HCTZ = hydrochlorthiazide; Hydral = hydralazine; ISDN = isosorbide dinitrate; KCI = potassium chloride; MI = myocardial infarction; NaCl = sodium chloride; NTG = nitroglycerin; PCA = procainamide; PRZ = prazosin; prop = propranolol; Q = quinidine. consent was obtained before electrophysiologic and radionuclide cineangiographic testing.
Criteria for exclusion were obstructive airways disease requiring sympathomimetic treatment; recent (less than 1 year) myocardial infarction or cardiovascular surgery; unstable angina pectoris; or any other severe concomitant illness, evidence for noncompliance or an inability to understand the nature of the investigation. Unlike a previous study,5 patients with heart failure or angina were not excluded.
Study Design ( fig. 1) The study was a prospective, 3-month, single-blind, placebo-controlled evaluation of encainide given orally every 6 hours using the antiarrhythmic response or appearance of side effects as the end point of dosage adjustments. The study had five sequential phases ( fig.  1 ). During the entire study, patients were given study drug capsules orally every 6 hours, which consisted of either encainide, 10-, 25- Phase 2, the dose-titration phase of the study, followed immediately unless delayed for 12-24 hours in order to perform electrophysiologic testing while on placebo treatment. During phase 2, patients began encainide therapy with 25 mg every 6 hours for at least 4 doses. Individual doses were increased at increments of 25 mg, provided patients remained at a given dose for at least 24 hours, the frequency of VPCs was not suppressed by more than 80% and side effects did not appear. When the VPC frequency decreased by approximately 80% as determined by multiple 8-hour segments of monitoring and the drug dosage was constant for 24 hours, a repeat 24-hour ambulatory ECG was done to confirm the effect of encainide on the frequency of VPCs. If the frequency of VPCs was not decreased by at least 80% before the onset of side effects, the patient was dropped from further participation. Before phase 3, the outpatient titration phase, electrophysiologic testing was again performed at the nadir of the chronic oral dose (i.e., 1-hour predose).
Phase 3 consisted of approximately four outpatient visits, 1 week apart. Dosage modifications were made as necessary to limit drug-related side effects and maintain effective outpatient control of the VPC frequency. Ambulatory ECG recordings were done to assure at least an 80% suppression of the VPC frequency after any dosage modifications. At the end of phase 3, a 24-hour ambulatory ECG recording was performed to confirm the effect of the established dose of encainide on the frequency of VPCs. Phase 4 involved inpatient continuous telemetric monitoring and began with the sudden withdrawal of encainide by replacement with the same number of identical placebo capsules every 6 hours. Patients were monitored using an on-line ECG analysis system for the appearance of an increased number of VPCs while on placebo. During the first 7 days, if semiquantitative review of 8-hour ECG monitoring records revealed a probable increase in VPC activity of greater than 50%, an ambulatory ECG recording was begun. If no increase in VPC frequency was observed, an ambulatory ECG recording was begun on the seventh day to confirm this observation and the patient was discontinued from further study. Fortyeight hours of ambulatory ECG recordings were obtained while the patient was on placebo. If symptomatic ventricular tachycardia (VT) occurred, placebo treatment was terminated.
At the conclusion of this second placebo phase (phase 4), maintenance treatment with encainide was reinstituted at the previously established dose to begin phase 5 ( fig. 1 ). This final phase included two outpatient visits 3 weeks apart and was terminated by a final 24-hour ambulatory recording.
A laboratory profile, including a complete blood count, platelet count, urinalysis, blood sugar, BUN, creatinine, SGOT, bilirubin, alkaline phosphatase, LDH, uric acid, serum electrolytes, calcium and fluorescent antinuclear antibody titer, was obtained before entry into the study and at the end of each phase. Fifteen-lead ECGs (12 standard leads and X, Y and Z orthogonal leads) were done each day during inpatient phases and at each outpatient visit. An ophthalmologic examination (including slit-lamp) was performed before beginning encainide during phase 2 and at the completion of the study.
Electrocardiographic Measurements
Standard 12-lead and X, Y and Z orthogonal ECGs were recorded at 25 mm/sec and 10 mm/mV (Marquette Data acquisition cart). In addition, a highresolution, signal-averaging computer was used to obtain summated and amplified electrocardiographic data displayed at a simulated speed of 100 mm/sec and amplitudes of 10, 200 and 4000 mm/mV (MAC-1, Hi Res module, Marquette Electronics).
All ECG measurements were made independently
by at least two of the investigators and without knowledge of the patient's study phase. The elevation of VPC frequency during each exercise test was accomplished by manual counts of VPCs taken from resting, peak exercise and tenth-minute postexercise rhythm strips (> 60 seconds each). Both the frequency and grade of ventricular arrhythmia were recorded for each period.
Radionuclide Cineangiography
Radionuclide cineangiography was performed with the subjects in a supine position at rest during maximum symptom-limited supine bicycle exercise as previously described.'7-'" The left ventricular ejection fraction was determined by computer-assisted analysis of left ventricle time-activity curves using a commercially available nuclear medicine computer system (Med. IV, Nova III computer, General Electric). Excellent correspondence (r = 0.90, p < 0.001, n = 32) of radionuclide ejection fractions with those obtained by contrast angiography has been established for this laboratory.20 After images were obtained at rest, supine bicycle exercise was begun with 100-kpm increments in exercise load at 2-minute intervals. Exercise was continued until limitation by severe fatigue, chest pain or severe dyspnea. Imaging was begun when the patient indicated moderate fatigue, and continued until the symptom-limited end point. Data acquired over the last 2-3 minutes of exercise were used to determine ejection fraction using the methods described above. Heart rate and blood pressure (measured using arm cuff sphygmomanometry) were recorded at 1-2-minute intervals during exercise.
Intracardiac Electrophysiologic Testing
Sixteen of the 21 patients in this study underwent sequential intracardiac electrophysiologic testing. Each of these patients underwent a baseline test during placebo therapy (phase 1); 12 patients (nos. 6-9, 11-16, 18 and 19) had an acute retest beginning 5 minutes after the bolus administration (over 5-7 minutes) of i.v. encainide (0.9 mg/kg body weight). These studies were completed in 20-40 minutes. Patients 1, 2, 4 and 5 had an acute retest 1-2 hours after 50 mg of oral encainide. Fifteen patients (1, 2, 4-9, 11-16, 18) underwent repeat testing after at least 48 hours of maintenance oral encainide therapy, referred to as the chronic test (during phase 2).
All patients were in the postabsorptive state, with only light diazepam sedation, if needed, when studied. Baseline tests were performed at the end of phase I and were followed by acute retesting after encainide. Catheters were introduced percutaneously into the right atrium across the tricuspid valve for His bundle recordings, and to the right ventricular apex for ventricular stimulation. Stimulation was performed with a specially designed programmable stimulator and the recordings were made on an Electronics for Medicine VR 16 recorder or Seimens Mingograf recorder 1650 with simultaneous recording on analog tape (Honeywell model 96). Stimulation was done with 2-msec square-wave impulses at twice diastolic threshold. At least three surface ECG leads were recorded (usually leads I, II and V1), as well as at least two intracardiac positions (His bundle, high right atrial or right ventricular apex). Baseline intervals were recorded at a paper speed of 150 mm/sec; stimulation studies were recorded at 75-100 mm/sec.
Measurements
Baseline measurements of the heart rate, P-wave duration, QRS duration, QT interval, PR interval, onset of P wave to the low right atrium (PA interval), AH fig. 2 ). Intraventricular reentrant beats were defined as beats with a horizontal or frontal QRS vector distinctly different from that of the stimulated beats and those that were not preceded by a His deflection.
In 12 of the 16 patients studied on placebo, the baseline study was followed by a 15-minute infusion of encainide (0.9 mg/kg body weight). The 2). During phase 3, however, patients 1 and 9 had episodes of nonfatal sustained VT, which is a higher grade of ventricular arrhythmia than that observed during phase 1 fig. 2) . The two patients with a nonrepetitive response on placebo remained the same after chronic oral encainide; six of the 10 patients with a nonsustained repetitive response became nonrepetitive on chronic oral encainide (fig. 2) . The three patients with a sustained repetitive response and three of the 10 patients with a nonsustained repetitive response improved to a nonrepetitive response during oral encainide treatment.
On follow-up (mean 12 months, range 10-14 months), all eight patients who had a nonrepetitive response to ventricular extrastimuli while on chronic oral encainide remained free of clinically recognized sustained VT. Seven of these eight had failed prior trials of antiarrhythmic therapy.
Seven of the 10 patients with a nonsustained repetitive response to extrastimuli on placebo did not improve during chronic oral encainide; six remained nonsustained and one became sustained ( fig. 2) . Compared with each of the eight patients with nonrepetitive responses on chronic encainide, only two of the seven patients with repetitive responses on chronic oral encainide remained free of clinically recognized sustained VT. Sustained VT was defined as VT longer than 1 minute in duration, requiring emergency medical intervention or accompanied by syncope. The other five patients (nos. 1, 9, 12, 15, 18) with repetitive responses on encainide demonstrated episodes of symptomatic sustained VT on follow-up despite confirmed suppression of greater than 80% of VPCs by encainide in all but one patient (no. 15). In this patient, sustained VT was a recurrence; it had also occurred before VPC suppression of 80% or more; however, in the other four patients, the sustained VT was a new clinical arrhythmia despite a 1-12-year history of VPCs. Patient 1 was dropped from further encainide treatment and has had no further episodes of sustained VT on a combination of tocainide and propranolol. In patients 12 and 18, sustained VT, recorded on treadmill exercise testing performed within 3 hours of oral encainide administration, did not occur at 6 hours. Arrhythmia (table 3) Fifteen of the 21 patients studied underwent sequential symptom-limited treadmill exercise tests, once on placebo and once on the dose of encainide that suppressed 80% of VPCs. Six patients did not undergo these studies, four because of severe cardiac limitations, one patient because of a physical handicap and one who died before adequate arrhythmia suppression. In each case, exercise was terminated because of fatigue, arrhythmia or chest pain. These limitations to continued exercise were not statistically different for encainide compared to placebo; however, both epi-sodes of new sustained VT observed on the treadmill occurred immediately after exercise during encainide treatment.
Hemodynamics at rest and peak exercise and the average exercise duration were not significantly different on encainide compared with placebo (table 3) . At rest, the mean maximum ST-segment depression for the group in any lead of the standard ECG on encainide tended to be greater than that on placebo, but this difference was not significant. At peak exercise, however, the maximum ST-segment depression in any lead of the standard ECG was significantly increased on encainide compared with placebo (p < 0.02; table 3).
Radionuclide Cineangiography (fig. 4, table 4) Sixteen of the 21 patients studied underwent sequential radionuclide cineangiographic studies, once on placebo and once on the dose of encainide that suppressed 80% of VPCs. Three patients did not undergo these studies, two who had very frequent VPCs that interfered with gated data acquisition and one who died before reaching an effective dose of encainide.
Completed studies in two patients were technically inadequate. The average interval between the two nuclear studies was 2.3 weeks (range 0.5-9 weeks). No patient had a cardiac event between studies. Radionuclide cineangiograms were performed at rest in each of the 16 patients and during exercise in 12 of these 16. Four patients could not exercise, three who had severe cardiac limitations and one patient who was physically handicapped.
The average ejection fraction, heart rate, systolic blood pressure and rate-pressure product at rest or with exercise in the 16 patients on maintenance encainide treatment were not significantly different from the average values on placebo treatment (table 4) . No patient had a change in ejection fraction at rest or with exercise exceeding 5 percent ( fig. 3) . Five percent represents the upper limits of variability established by sequential testing in 14 other patients who did not undergo drug intervention.
A separate analysis of ejection fractions determined at rest and at peak exercise stress on encainide were performed with patients stratified according to the preexisting level of resting left ventricular function during placebo treatment. Six patients with preexisting left ventricular functional impairment (defined as an average ejection fraction of 45% or less) were compared with 10 patients in whom left ventricular function at rest was not significantly impaired (ejection fraction greater than 45%). Encainide was not associated with a change in ejection fraction, peak heart rate, systolic blood pressure or rate-pressure product in either group (table 4, fig. 3 ).
Electrocardiograms (table 5) All patients were in sinus rhythm. One patient who was treated with propranolol showed a prolonged PR interval (>0.20 second) and only one patient had a prolonged QRS of greater than 0.12 second on placebo treatment. All other patients had normal PR intervals and QRS durations. During encainide treatment, 14 patients (67%) developed first-degree AV block; the maximum PR interval observed in two patients was 0.28 second. One patient who inadvertently received 100 mg every 6 hours of encainide for 48 hours instead of 50 mg every 6 hours demonstrated a transient type 2 second-degree AV block, right bundle branch block and asymptomatic sinus pauses (< 3 seconds). No patient had greater than first-degree AV block on the dosage found effective in suppressing 80% of VPCs.
Compared with placebo, oral encainide produced a significant prolongation in P-wave duration, PR interval, QRS duration, QT interval and corrected QT interval. Intraatrial conduction time, reflected by the P terminal force in lead V1, increased 54%, though inter- Normal sinoatrial recovery times (corrected) and normal sinoatrial conduction times22 in 12 patients remained normal on encainide; however, abnormal control sinoatrial recovery times in two patients became even more prolonged after treatment with encainide. Each of these patients and another patient, who had sinus dysfunction for the first time after encainide, developed dose-related sinus pauses on encainide that were infrequent and of minor degree (all shorter than 3 seconds).
Intracardiac conduction intervals were uniformly prolonged after oral encainide treatment in all 15 of 21 patients studied (fig. 4) . The HV interval increased by the largest percentage change; however, the observed prolongation in the PR interval produced by encainide resulted from similar absolute delays in the subintervals of proximal and distal conduction (table 5) .
Encainide produced a significant increase in the Wenckebach cycle length, atrial, AV nodal and ventricular refractory periods ( curring within 2 hours of administration) and in only one patient, with preexisting visual impairment, did minor side effects preclude continued treatment with encainide. During this trial, three patients had a worsening of CHF, one patient during both placebo and encainide treatments, one during placebo treatment and one during encainide treatment.
Two patients died, one of refractory CHF and one of refractory VT (associated with a probable inferior wall myocardial infarction). Both patients were in New York Heart Association functional class IV, one with angina and one with heart failure, and each had been successfully resuscitated from spontaneous ventricular fibrillation in the month before entry into the study. Oral encainide produced significant prolongations of the PR, QRS, QT and corrected QT intervals on standard ECG in this group. The prolongation of ECG intervals by encainide was studied by Roden and others.5-7 Intracardiac electrophysiologic measurements confirmed that the PA, AH and HV intervals and the atrial, AV nodal and ventricular effective refractory periods were significantly prolonged after encainide. Sami et al.1' studied acute i.v. administration, with results similar tb those of our study. The present study is the first to show that the acute changes in ECG intervals and refractory period changes produced by single-dose i.v. encainide are similar to those produced by chronic oral encainide. In each instance, the HV interval and QRS duration during the nadir of chronic therapy (at dosages sufficient to suppress VPCs by > 80%) exceeded the changes observed after acute i.v. administration of encainide. In addition, blood levels of free encainide showed strikingly lower values on chronic therapy compared with acute i.v. therapy. These observations suggest that the more prolonged and greater effect of chronic oral therapy on intraventricular conduction compared with i.v. therapy is due to either a build-up of an active and unmeasured metabolite with a longer biologic half-life or to the presence of a deep compartment for encainide at its site of action.5 7 Since the metabolism of encainide may proceed rapidly after it is administered, the accumulation of metabolite in concert with the activity of free encainide probably accounted for the acute changes in this study. The presence of an 0-demethyl metabolite of encainide was confirmed to act synergistically with free encainide in an in vitro preparation.7
While the intracardiac evaluation of ventricular vulnerability is not a standard clinical method, this technique appears to offer important prognostic information.23 33 3 The ability to induce VT that is morphologically similar to the clinical event without treatment and observe its disappearance with drug administration has been correlated with long-term success in arrhythmia control.35 --Three responses in our patient group, during intracardiac provocative testing after initial i.v. or chronic nadir encainide treatment, were associated with long-term success in ventricular arrhythmia control: the disappearance of induced VT in three patients, disappearance of repetitive firing of greater than one beat in three patients and the persistence of a nonrepetitive response in two patients. These eight patients have done well on chronic encainide. In contrast, five of the other seven patients, who showed persistent or increased repetitive responses to ventricular extrastimulation, have had a significantly higher incidence of recurrent ventricular arrhythmia (exclusively sustained VT). The substrate for repetitive firing, coupled with the prolongation of conduction times produced by encainide, may have increased the ability to sustain reentry circuits in patients with a higher incidence of recurrent arrhythmia. The patients at risk for new, sustained VT were indistinguishable from others by virtue of similar prolongation of ECG intervals and refractory periods and similar VPC suppression. Hence, no apparent 
